Compare SaaS Products
Compare up to 4 software products side by side. Find the best solution for your business.
Add Products to Compare
2 of 4 products selected
| Feature | ||
|---|---|---|
| Rating |
4.1
|
4.0
|
| Reviews | 15 | 8 |
| Category | Biotech | Biotech |
| Description |
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma. |
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford. |
| Website | http://www.erisbio.com | https://www.evolverebiosciences.com/ |
| Positives |
"Has significantly improved our team's productivity."
Shanie Barton - 5/5
|
"Outstanding performance and great documentation."
Mr. Sigurd Marquardt - 5/5
|
| Negatives |
"Customer support was slow to respond to our issues."
Mr. Cleveland Pouros - 1/5
|
"Not quite what we expected. Lacking some key features."
Juanita Hodkiewicz - 1/5
|
| Details | View Full Review → | View Full Review → |
